PMID- 35780303
OWN - NLM
STAT- MEDLINE
DCOM- 20220725
LR  - 20220725
IS  - 1349-9157 (Electronic)
IS  - 0449-3060 (Print)
IS  - 0449-3060 (Linking)
VI  - 63
IP  - 4
DP  - 2022 Jul 19
TI  - Comparing the toxicity and disease control rate of radiotherapy for prostate 
      cancer between salvage settings after high-intensity focused ultrasound therapy 
      and initial settings.
PG  - 675-683
LID - 10.1093/jrr/rrac039 [doi]
AB  - The purpose of this retrospective study was to compare the toxicity and disease 
      control rate of radiotherapy for prostate cancer in salvage settings after 
      high-intensity focused ultrasound (HIFU) therapy (HIFU cohort) with those in 
      radical settings (non-HIFU cohort). From 2012 to 2020, 215 patients were 
      identified for this study and 17 were treated in the salvage settings after HIFU. 
      The median follow-up time was 34.5 months (range: 7-102 months, inter-quartile 
      range [IQR]: 16-64 months). Genitourinary (GU) and gastrointestinal (GI) adverse 
      events were evaluated in acute and late periods with Common Terminology Criteria 
      for Adverse Events version 5, and the rates of biochemical-clinical failure free 
      survival (BCFS) and overall survival (OS) were estimated. The cumulative 
      incidence of late GU Grade 2 or greater toxicity after five years was 
      significantly different between the non-HIFU and HIFU cohorts with rates of 7.3% 
      and 26.2%, respectively (P = 0.03). Regarding GI Grade 2 or greater toxicity, 
      there was no significant difference between the two cohorts. The 5y-BCFS was 
      84.2% in the non-HIFU cohort and 69.5% in the HIFU cohort with no significant 
      difference (P = 0.10) and the 5y-OS was 95.9% and 92.3%, respectively (P = 0.47). 
      We concluded that the possibility of increased late GU Grade 2 or greater should 
      be considered when applying salvage radiotherapy for local recurrence after HIFU.
CI  - (c) The Author(s) 2022. Published by Oxford University Press on behalf of The 
      Japanese Radiation Research Society and Japanese Society for Radiation Oncology.
FAU - Kuroki, Toshihisa
AU  - Kuroki T
AD  - Department of Radiation Oncology, Tokai University Hachioji Hospital, 1838 
      Ishikawamachi, Hachioji, Tokyo 192-0032, Japan.
FAU - Shoji, Sunao
AU  - Shoji S
AD  - Department of Urology, Tokai University School of Medicine, 143 Shimokasuya, 
      Isehara, Kanagawa 259-1193, Japan.
FAU - Uchida, Toyoaki
AU  - Uchida T
AD  - Department of Urology, Tokai University School of Medicine, 143 Shimokasuya, 
      Isehara, Kanagawa 259-1193, Japan.
FAU - Akiba, Takeshi
AU  - Akiba T
AD  - Department of Radiation Oncology, Tokai University Hachioji Hospital, 1838 
      Ishikawamachi, Hachioji, Tokyo 192-0032, Japan.
FAU - Kabuki, Shigeto
AU  - Kabuki S
AD  - Department of Radiation Oncology, Tokai University School of Medicine, 143 
      Shimokasuya, Isehara, Kanagawa 259-1193, Japan.
FAU - Nagao, Ryuta
AU  - Nagao R
AD  - Department of Radiation Oncology, Tokai University School of Medicine, 143 
      Shimokasuya, Isehara, Kanagawa 259-1193, Japan.
FAU - Fukuzawa, Tsuyoshi
AU  - Fukuzawa T
AD  - Department of Radiation Oncology, Tokai University School of Medicine, 143 
      Shimokasuya, Isehara, Kanagawa 259-1193, Japan.
FAU - Matsumoto, Yoshitsugu
AU  - Matsumoto Y
AD  - Department of Radiation Oncology, Tokai University School of Medicine, 143 
      Shimokasuya, Isehara, Kanagawa 259-1193, Japan.
FAU - Katsumata, Tomomi
AU  - Katsumata T
AD  - Department of Radiation Oncology, Tokai University School of Medicine, 143 
      Shimokasuya, Isehara, Kanagawa 259-1193, Japan.
FAU - Futakami, Natsumi
AU  - Futakami N
AD  - Department of Radiation Oncology, Tokai University Hachioji Hospital, 1838 
      Ishikawamachi, Hachioji, Tokyo 192-0032, Japan.
FAU - Mikami, Tatsuya
AU  - Mikami T
AD  - Department of Radiation Oncology, Tokai University School of Medicine, 143 
      Shimokasuya, Isehara, Kanagawa 259-1193, Japan.
FAU - Nakano, Yoji
AU  - Nakano Y
AD  - Department of Radiation Oncology, Tokai University School of Medicine, 143 
      Shimokasuya, Isehara, Kanagawa 259-1193, Japan.
FAU - Toyoda, Yuri
AU  - Toyoda Y
AD  - Department of Radiation Oncology, Tokai University School of Medicine, 143 
      Shimokasuya, Isehara, Kanagawa 259-1193, Japan.
FAU - Takazawa, Tsuyoshi
AU  - Takazawa T
AD  - Department of Radiation Oncology, Tokai University School of Medicine, 143 
      Shimokasuya, Isehara, Kanagawa 259-1193, Japan.
FAU - Kunieda, Etsuo
AU  - Kunieda E
AD  - Department of Radiation Oncology, Tokai University School of Medicine, 143 
      Shimokasuya, Isehara, Kanagawa 259-1193, Japan.
FAU - Sugawara, Akitomo
AU  - Sugawara A
AD  - Department of Radiation Oncology, Tokai University School of Medicine, 143 
      Shimokasuya, Isehara, Kanagawa 259-1193, Japan.
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Radiat Res
JT  - Journal of radiation research
JID - 0376611
SB  - IM
MH  - *Extracorporeal Shockwave Therapy
MH  - Humans
MH  - Male
MH  - Neoplasm Recurrence, Local/radiotherapy
MH  - *Prostatic Neoplasms/radiotherapy
MH  - Retrospective Studies
MH  - Salvage Therapy
MH  - Treatment Outcome
PMC - PMC9303605
OTO - NOTNLM
OT  - high-intensity focused ultrasound (HIFU)
OT  - prostate
OT  - radiotherapy
OT  - salvage
EDAT- 2022/07/04 06:00
MHDA- 2022/07/26 06:00
PMCR- 2022/07/02
CRDT- 2022/07/03 02:12
PHST- 2022/02/17 00:00 [received]
PHST- 2022/04/18 00:00 [revised]
PHST- 2022/07/04 06:00 [pubmed]
PHST- 2022/07/26 06:00 [medline]
PHST- 2022/07/03 02:12 [entrez]
PHST- 2022/07/02 00:00 [pmc-release]
AID - 6627562 [pii]
AID - rrac039 [pii]
AID - 10.1093/jrr/rrac039 [doi]
PST - ppublish
SO  - J Radiat Res. 2022 Jul 19;63(4):675-683. doi: 10.1093/jrr/rrac039.